These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 37567965)
1. The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism. Leow BCS; Kok CH; Yeung DT; Hughes TP; White DL; Eadie LN Sci Rep; 2023 Aug; 13(1):13110. PubMed ID: 37567965 [TBL] [Abstract][Full Text] [Related]
2. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy. Ferri C; Bianchini M; Bengió R; Larripa I Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144 [TBL] [Abstract][Full Text] [Related]
3. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928 [TBL] [Abstract][Full Text] [Related]
5. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711 [TBL] [Abstract][Full Text] [Related]
6. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109 [TBL] [Abstract][Full Text] [Related]
7. Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells. Tsubaki M; Takeda T; Koumoto Y; Usami T; Matsuda T; Seki S; Sakai K; Nishio K; Nishida S Cell Prolif; 2023 Jun; 56(6):e13420. PubMed ID: 36847709 [TBL] [Abstract][Full Text] [Related]
8. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome. Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693 [TBL] [Abstract][Full Text] [Related]
9. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1 Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618 [TBL] [Abstract][Full Text] [Related]
10. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. Parker WT; Lawrence RM; Ho M; Irwin DL; Scott HS; Hughes TP; Branford S J Clin Oncol; 2011 Nov; 29(32):4250-9. PubMed ID: 21990409 [TBL] [Abstract][Full Text] [Related]
11. A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line. Airiau K; Turcq B; Mahon FX; Belloc F Leuk Res; 2017 Oct; 61():44-52. PubMed ID: 28888102 [TBL] [Abstract][Full Text] [Related]
12. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1 Gleixner KV; Sadovnik I; Schneeweiss M; Eisenwort G; Byrgazov K; Stefanzl G; Berger D; Herrmann H; Hadzijusufovic E; Lion T; Valent P Leuk Res; 2019 Mar; 78():36-44. PubMed ID: 30711891 [TBL] [Abstract][Full Text] [Related]